Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
333 hedge funds and large institutions have $6.5B invested in Intra-Cellular Therapies Inc. in 2023 Q4 according to their latest regulatory filings, with 73 funds opening new positions, 109 increasing their positions, 112 reducing their positions, and 27 closing their positions.
170% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 27
111% more call options, than puts
Call options by funds: $58.1M | Put options by funds: $27.5M
43% more capital invested
Capital invested by funds: $4.54B → $6.5B (+$1.96B)
25% more funds holding in top 10
Funds holding in top 10: 8 → 10 (+2)
14% more funds holding
Funds holding: 292 → 333 (+41)
3% less repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 112
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$130M |
| 2 |
Morgan Stanley
New York
|
+$89.1M |
| 3 |
BlackRock
New York
|
+$39M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$34.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$31.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$62.2M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$35.1M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$34.5M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$23.8M |
| 5 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$17.2M |
ITCI Hedge Fund Activity: Q4 2023 in Review
333 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2023, worth a combined $6.5B — up 43% from $4.54B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new ITCI positions and 27 closed out — a net gain of 46 holders — while 109 added to existing stakes and 112 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $130M. The largest seller was Woodline Partners, exiting entirely with an estimated $62.2M sold.
- 333 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2023, up from 292 in Q3 2023.
- Funds reported $6.5B of Intra-Cellular Therapies Inc. stock for Q4 2023, up 43% quarter-over-quarter.
- 73 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2023 and 27 closed out, a net change of +46 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q4 2023 was Avoro Capital Advisors, an estimated $130M added.
- The largest Intra-Cellular Therapies Inc. seller in Q4 2023 was Woodline Partners, an estimated $62.2M sold.
Based on aggregated 13F filings for Q4 2023.